Salvational Intervention for Reducing AECOPD Under Severe Air Pollution

COPD Exacerbation Clinical Trial

— SIRCAP  

Official title:

A Prospective Study of Salvational Intervention With ICS/LABA for Reducing Chronic Obstructive Pulmonary Disease Exacerbation Under Severe Air Pollution (SIRCAP) in Beijing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03083067
• Other study ID #: SF2016-1-4071
• Status: Completed
• Phase: N/A
• Start date: March 20, 2017
• Est. completion date: March 16, 2022

Study information

• Verified date: March 2022
• Source: Peking University First Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, prospective, randomized and standard treatment parallel control clinical trial.A total of 764 stable COPD patients according to GOLD will be recruited and equally divided into two parallel groups, salvational intervention group (SI group) and control group (CT group).On the foundation of basic medicine, inhaled ICS/LABA will be used as an intervention drug for patients in SI group on severe air pollution days. It is aimed to evaluate whether this novel treatment strategy will decrease the frequency of AECOPD per year.

Description:

This is a multi-center, prospective, randomized and standard treatment parallel control clinical trial. A total of 764 stable COPD patients with history of exacerbation according to GOLD will be recruited and equally divided into two parallel groups, salvational intervention group (SI group) and control group (CT group). The randomization is stratified by medical center and the random code is designed in a 1:1 ratio. The Department of Respiratory and Critical Care of Peking University First Hospital is responsible for this research. Other 10 units participating in the study include Peking University Shougang Hospital, People's Hospital of Beijing Daxing District, Beijing Jingmei Group General Hospital, Beijing Miyun Hospital, Beijing Changping Hospital, The Hospital of Shunyi District Beijing, Beijing Luhe Hospital Capital Medical University, Civil Aciation General Hospital, Beijing Jishuitan Hospital and Aerospace 731 Hospital. These 11 centers approximately cover area from urban to suburbs in Beijing.

Inhaled tiotropium bromide(18ug), budesonide/formoterol（160ug/4.5ug）or tiotropium bromide(18ug)+ budesonide/formoterol （160ug/4.5ug）will be used as basic medicine. On the foundation of basic medicine, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in SI group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200. CT group maintains the original treatment. Besides baseline, patients will be formally visited 4 or 5 times during this trial: before randomization (for those who need pharmacological washout) and every six months after randomization.

Primary outcome is the frequency of AECOPD per year, which is defined as the frequency of AECOPD/the number of patients/year. Secondary outcomes include the number of unplanned outpatient visits, emergency medical visits, hospitalization, medical expense and mortality caused by AECOPD per year.

The study protocol has been approved by the Peking University First Hospital Institutional Review Board (IRB) (2016[1032]). Any protocol modifications will be submitted for the IRB review and approval.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 402
• Est. completion date: March 16, 2022
• Est. primary completion date: March 16, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

1. aged at 40-80 years old;

2. spirometry confirmed diagnose of COPD with at least once exacerbation before, and stable for at least three months;

3. quit smoking for more than six months;

4. be able to engage in daily activities;

5. have willing to participate in this study, follow the research program and have the ability to sign the informed consent;

6. Beijing residents;

7. can be contacted;

Exclusion Criteria:

1. history of asthma, lung cancer, active pulmonary tuberculosis, bronchiectasis, diffuse lung disease (interstitial pneumonia, pulmonary sarcoidosis, occupational lung disease, sarcoidosis et al) and pleural disease;

2. history of lobectomy and / or lung transplantation;

3. predicted life expectancy less than 3 years;

4. history of severe psychiatric illnesses, mental disorders, neurological disorders, malignant tumors, chronic liver disease, heart failure, autoimmune diseases, chronic kidney disease;

5. Never engage in outdoor activities;

6. plan to move out of Beijing in 3 years

7. Plan to carry out an indoor redecoration during the study;

8. Alcoholism, drug abuse or abuse of toxic solvents;

9. Allergic to the study drug or its ingredients, or have a clear contraindication of it;

10. Participation in another clinical trial;

11. Cannot finish long term follow-up or poor compliance;

12. Do not provide consent.

Related Conditions & MeSH terms

• Air Pollution
• COPD Exacerbation

Intervention

Drug:
• Budesonide/formoterol
On the foundation of basic treatment strategies, inhaled budesonide/formoterol(160ug/4.5ug)will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol(160ug/4.5ug)twice a day until the third day after AQI drops below 200.
• tiotropium bromide
Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.

Locations

Country	Name	City	State
China	Aerospace 731 Hospital	Beijing	Beijing
China	Beijing Changping Hospital	Beijing	Beijing
China	Beijing Jingmei Group General Hospital	Beijing	Beijing
China	Beijing Jishuitan Hospital	Beijing	Beijing
China	Beijing Luhe Hospital	Beijing	Beijing
China	Beijing Miyun Hospital	Beijing	Beijing
China	Civil Aviation General Hospital	Beijing	Beijing
China	Peking University First Hospital	Beijing	Beijing
China	Peking University Shougang Hospital	Beijing	Beijing
China	People's Hospital of Beijing Daxing District	Beijing	Beijing
China	The Hospital of Shunyi District Beijing	Beijing	Beijing

Sponsors (11)

Lead Sponsor	Collaborator
Peking University First Hospital	Aerospace 731 Hospital, Beijing Changping Hospital, Beijing Jingmei Group General Hospital, Beijing Jishuitan Hospital, Beijing Luhe Hospital, Beijing Miyun Hospital, Civil Aviation General Hospital, Peking University Shougang Hospital, People's Hospital of Beijing Daxing District, The Hospital of Shunyi District Beijing

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the frequency of exacerbation of COPD per year		3 year
Secondary	the number of unplanned outpatient visits caused by exacerbation of COPD per year		3 years
Secondary	the number of unplanned emergency medical visits caused by exacerbation of COPD per year		3 years
Secondary	the number of unplanned hospitalization caused by exacerbation of COPD per year		3 years
Secondary	the cost of unplanned medical expense caused by exacerbation of COPD per year		3 years
Secondary	the number of unplanned mortality caused by exacerbation of COPD per year		3 years